Ignite Creation Date:
2024-05-06 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 2:21 PM
Study NCT ID:
NCT05174143
Status:
COMPLETED
Last Update Posted:
2021-12-30
First Post:
2021-12-14
Brief Title:
Personalized Antiplatelet Therapy in CAD Patients
Sponsor:
Xinjiang Medical University
Organization:
Xinjiang Medical University
Study Overview
Official Title:
Personalized Antiplatelet Therapy According to CYP2C19 Genotype in Coronary Artery Disease A Real World Study
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective no-randomized single-center study performed on 15000 consecutive coronary artery patients from Dec 2016 to Oct 2021 All these patients were detected CYP2C19 genotype The antiplatelet treatment was recorded according to the therapy actually adopted by the patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None